Show simple item record

Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial

dc.contributor.authorAckermann, Deonna M.
dc.contributor.authorSmit, Amelia K.
dc.contributor.authorJanda, Monika
dc.contributor.authorvan Kemenade, Cathelijne H.
dc.contributor.authorDieng, Mbathio
dc.contributor.authorMorton, Rachael L.
dc.contributor.authorTurner, Robin M.
dc.contributor.authorCust, Anne E.
dc.contributor.authorIrwig, Les
dc.contributor.authorHersch, Jolyn K.
dc.contributor.authorGuitera, Pascale
dc.contributor.authorSoyer, H. Peter
dc.contributor.authorMar, Victoria
dc.contributor.authorSaw, Robyn P.M.
dc.contributor.authorLow, Donald
dc.contributor.authorLow, Cynthia
dc.contributor.authorDrabarek, Dorothy
dc.contributor.authorEspinoza, David
dc.contributor.authorEmery, Jon
dc.contributor.authorMurchie, Peter
dc.contributor.authorThompson, John F.
dc.contributor.authorScolyer, Richard A.
dc.contributor.authorAzzi, Anthony
dc.contributor.authorLilleyman, Alister
dc.contributor.authorBell, Katy J.L.
dc.date.accessioned2021-05-26T08:54:01Z
dc.date.available2021-05-26T08:54:01Z
dc.date.issued2021-05-04
dc.identifier.citationAckermann , D M , Smit , A K , Janda , M , van Kemenade , C H , Dieng , M , Morton , R L , Turner , R M , Cust , A E , Irwig , L , Hersch , J K , Guitera , P , Soyer , H P , Mar , V , Saw , R P M , Low , D , Low , C , Drabarek , D , Espinoza , D , Emery , J , Murchie , P , Thompson , J F , Scolyer , R A , Azzi , A , Lilleyman , A & Bell , K J L 2021 , ' Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial ' , Trials , vol. 22 , no. 1 , 324 . https://doi.org/10.1186/s13063-021-05231-7en
dc.identifier.issn1745-6215
dc.identifier.otherPURE: 193911993
dc.identifier.otherPURE UUID: 814be9a5-5f64-47ee-9995-23dcc39b07cf
dc.identifier.otherScopus: 85105502711
dc.identifier.otherPubMed: 33947444
dc.identifier.otherORCID: /0000-0001-9968-5991/work/95223184
dc.identifier.urihttps://hdl.handle.net/2164/16541
dc.descriptionThis research project is funded by a National Health and Medical Research Council (NHMRC) Project grant (#1163054). The funder had no role in the design of the study and will have no role in the collection, analysis, and interpretation of the data; the writing of the report; or the decision to submit the report for publication. Funding Information: AEC is funded by a Career Development Fellowship from the National Health and Medical Research Council (NHMRC; 1147843). JFT is a recipient of an NHMRC Program Grant (1093017). RPMS is supported by Melanoma Institute Australia. RAS is supported by a NHMRC Program Grant and Practitioner Fellowship. For RAS, support from the from colleagues at Melanoma Institute Australia, Royal Prince Alfred Hospital and NSW Health Pathology is also gratefully acknowledged. RLM is supported with an NHMRC Investigator grant (1194703) and a University of Sydney Robinson Fellowship. HPS holds an NHMRC MRFF Next Generation Clinical Researchers Program Practitioner Fellowship (APP1137127). JH is supported by an NHMRC Early Career Fellowship (1112509). KB is supported by an NHMRC Investigator Grant (1174523) and a University of Sydney Research Accelerator (SOAR) Prize.en
dc.format.extent18
dc.language.isoeng
dc.relation.ispartofTrialsen
dc.rightsThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.en
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectCancer surveillanceen
dc.subjectEarly detection of canceren
dc.subjectHealth services researchen
dc.subjectMelanomaen
dc.subjectRandomised controlled trialen
dc.subjectSelf-examinationen
dc.subjectTeledermoscopyen
dc.subjectTelehealthen
dc.subjectR Medicineen
dc.subjectMedicine (miscellaneous)en
dc.subjectPharmacology (medical)en
dc.subjectOtheren
dc.subject1147843en
dc.subject1163054en
dc.subject1093017en
dc.subject1194703en
dc.subjectAPP1137127en
dc.subject1174523en
dc.subjectSupplementary Informationen
dc.subject.lccRen
dc.titleCan patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trialen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Centre for Health Data Scienceen
dc.contributor.institutionUniversity of Aberdeen.Clinical Medicineen
dc.contributor.institutionUniversity of Aberdeen.Data Safe Havenen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1186/s13063-021-05231-7
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85105502711&partnerID=8YFLogxKen


Files in this item

Thumbnail
Name:
Ackermann_etal_can_patient_led ...
Size:
2.192Mb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record